The Connecticut State Legislature has introduced Senate Bill 11, aimed at addressing the rising costs of prescription drugs through the potential establishment of a Canadian prescription drug importation program. Introduced on March 6, 2025, the bill seeks to empower the Commissioner of Consumer Protection to conduct a feasibility study on this initiative, with a report due by October 1, 2027.

The bill outlines key definitions relevant to the pharmaceutical distribution supply chain, including terms such as "participating wholesaler," "recall," and "track-and-trace." These definitions are crucial for ensuring clarity in the implementation of the proposed program. The initiative is designed to allow wholesalers to distribute prescription drugs sourced from Canadian suppliers, potentially providing a more affordable alternative for Connecticut residents.

Debate surrounding Senate Bill 11 has highlighted concerns about the safety and regulation of imported drugs, as well as the implications for local pharmacies and the pharmaceutical industry. Proponents argue that the bill could significantly lower drug costs for consumers, while opponents caution against the risks associated with drug quality and the complexities of international supply chains.

The economic implications of the bill are significant, as high prescription drug prices have been a persistent issue affecting many residents. If successful, the program could lead to substantial savings for consumers and reduce the financial burden on the state's healthcare system. However, the bill's future remains uncertain, pending the results of the feasibility study and subsequent legislative discussions.

As Connecticut moves forward with this initiative, the outcomes of the study will be critical in determining whether the state will implement a Canadian drug importation program, potentially setting a precedent for other states grappling with similar challenges in prescription drug affordability.